General Information of Drug (ID: DMHKJ5I)

Drug Name
Nabiximols
Synonyms
Nabiximols; Sativex; GW-1000; Cannador; Nabiximols [USAN]; GW1000; GW 1000; Tetrahydrocannabinol-cannabidiol combination; Cannabidiol mixture with Tetrahydrocannabinol; delta-9-Tetrahydrocannabinol and cannabidiol; Cannabidiol and delta-9-tetrahydrocarnabinol; GW-1000-02
Indication
Disease Entry ICD 11 Status REF
Cancer related pain MG30 Phase 3 [1]
Muscle spasm MB47.3 Phase 3 [2]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski):
1
Molecular Weight 628.9
Logarithm of the Partition Coefficient Not Available
Rotatable Bond Count 10
Hydrogen Bond Donor Count 3
Hydrogen Bond Acceptor Count 4
ADMET Property
Half-life
The concentration or amount of drug in body reduced by one-half in 24 - 36 hours [3]
Metabolism
The drug is metabolized via the liver []
Chemical Identifiers
Formula
C42H60O4
IUPAC Name
(6aR,10aR)-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydrobenzo[c]chromen-1-ol;2-[(6R)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]-5-pentylbenzene-1,3-diol
Canonical SMILES
CCCCCC1=CC(=C(C(=C1)O)C2C=C(CC[C@H]2C(=C)C)C)O.CCCCCC1=CC(=C2[C@@H]3C=C(CC[C@H]3C(OC2=C1)(C)C)C)O
InChI
InChI=1S/2C21H30O2/c1-5-6-7-8-15-12-18(22)20-16-11-14(2)9-10-17(16)21(3,4)23-19(20)13-15;1-5-6-7-8-16-12-19(22)21(20(23)13-16)18-11-15(4)9-10-17(18)14(2)3/h11-13,16-17,22H,5-10H2,1-4H3;11-13,17-18,22-23H,2,5-10H2,1,3-4H3/t16-,17-;17-,18?/m10/s1
InChIKey
SSNHGLKFJISNTR-FWUPRJFYSA-N
Cross-matching ID
PubChem CID
44148067
CAS Number
56575-23-6
DrugBank ID
DB14011
TTD ID
D0C5CE
INTEDE ID
DR1121
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [4]
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Substrate [5]
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Substrate [6]
Mephenytoin 4-hydroxylase (CYP2C19) DEGTFWK CP2CJ_HUMAN Substrate [6]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Substrate [5]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Actin, cytoplasmic 1 (ACTB) OT1MCP2F ACTB_HUMAN Gene/Protein Processing [7]
Alpha-1-antitrypsin (SERPINA1) OTACYW9J A1AT_HUMAN Gene/Protein Processing [7]
E3 ubiquitin-protein ligase DTX3L (DTX3L) OTCCO2QZ DTX3L_HUMAN Gene/Protein Processing [7]
Fructose-bisphosphate aldolase A (ALDOA) OTWRFTIB ALDOA_HUMAN Gene/Protein Processing [7]
Guanylate-binding protein 5 (GBP5) OTS4AO4A GBP5_HUMAN Gene/Protein Processing [7]
Histone H4 (H4C1) OTB71W46 H4_HUMAN Gene/Protein Processing [7]
Large ribosomal subunit protein uL6 (RPL9) OTKE01O8 RL9_HUMAN Gene/Protein Processing [7]
Lymphocyte-specific protein 1 (LSP1) OTSPSIFO LSP1_HUMAN Gene/Protein Processing [7]
Neurogranin (NRGN) OTVGE10W NEUG_HUMAN Gene/Protein Processing [7]
Nuclear factor NF-kappa-B p105 subunit (NFKB1) OTNRRD8I NFKB1_HUMAN Gene/Protein Processing [7]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 Clinical pipeline report, company report or official report of GW Pharmaceuticals.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
4 Pharmacokinetic evaluation of nabiximols for the treatment of multiple sclerosis pain. Expert Opin Drug Metab Toxicol. 2013 Sep;9(9):1219-28.
5 Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: a systematic review. Drug Metab Rev. 2014 Feb;46(1):86-95.
6 Molecular targets of cannabidiol in neurological disorders. Neurotherapeutics. 2015 Oct;12(4):699-730.
7 Clinical response to Nabiximols correlates with the downregulation of immune pathways in multiple sclerosis. Eur J Neurol. 2018 Jul;25(7):934-e70. doi: 10.1111/ene.13623. Epub 2018 Apr 16.